Clinical Trials Logo

Stage II Gallbladder Cancer clinical trials

View clinical trials related to Stage II Gallbladder Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02042443 Active, not recruiting - Clinical trials for Advanced Adult Hepatocellular Carcinoma

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Start date: February 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving trametinib is more effective than combination chemotherapy in treating patients with biliary or gallbladder cancer.

NCT ID: NCT01859182 Withdrawn - Clinical trials for Advanced Adult Primary Liver Cancer

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well selumetinib and Akt inhibitor MK-2206 work in treating patients with refractory or advanced gallbladder or bile duct cancer that cannot be removed by surgery. Selumetinib and Akt inhibitor MK-2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00075504 Completed - Clinical trials for Stage IIIA Gallbladder Cancer

Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer

Start date: November 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving 3-AP together with gemcitabine works in treating patients with unresectable or metastatic bile duct or gallbladder cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may help gemcitabine kill more cancer cells by making them more sensitive to the drug.